亿帆医药：控股子公司在研产品F-652新增适应症移植物抗宿主病获临床试验批准

Core Viewpoint - Yifan Pharmaceutical's subsidiary Yiyisheng Biotechnology has received approval from the National Medical Products Administration for the clinical trial of F-652, a novel drug aimed at treating graft-versus-host disease (GVHD) [1] Group 1: Product Development - F-652 is a recombinant human interleukin 22-Fc fusion protein developed using the company's proprietary Di-KineTM dual-molecule technology platform [1] - The drug is the first of its kind (Class 1 innovative biopharmaceutical) and is designed to mimic the activity of natural interleukin 22 in the body [1] - The Fc fragment fused to the drug significantly extends its half-life, thereby enhancing clinical efficacy [1] Group 2: Clinical Trial Approval - The National Medical Products Administration has granted a Clinical Trial Approval Notice for the Phase II clinical trial of F-652 [1] - This approval marks a significant milestone in the development of F-652 for treating GVHD [1]